Westover Capital Advisors LLC Sells 68 Shares of Johnson & Johnson (NYSE:JNJ)

Westover Capital Advisors LLC reduced its holdings in Johnson & Johnson (NYSE:JNJ) by 1.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,983 shares of the company’s stock after selling 68 shares during the quarter. Westover Capital Advisors LLC’s holdings in Johnson & Johnson were worth $865,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of JNJ. Wealth Group Ltd. bought a new position in shares of Johnson & Johnson during the third quarter worth about $213,000. Swedbank AB grew its holdings in shares of Johnson & Johnson by 5.3% during the third quarter. Swedbank AB now owns 2,215,108 shares of the company’s stock worth $358,980,000 after buying an additional 111,570 shares in the last quarter. ASB Consultores LLC grew its holdings in shares of Johnson & Johnson by 5.2% during the third quarter. ASB Consultores LLC now owns 5,061 shares of the company’s stock worth $820,000 after buying an additional 248 shares in the last quarter. United Advisor Group LLC grew its holdings in shares of Johnson & Johnson by 18.7% during the third quarter. United Advisor Group LLC now owns 5,563 shares of the company’s stock worth $902,000 after buying an additional 876 shares in the last quarter. Finally, Clarity Financial LLC grew its holdings in shares of Johnson & Johnson by 9.7% during the third quarter. Clarity Financial LLC now owns 6,371 shares of the company’s stock worth $1,032,000 after buying an additional 561 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the firm’s stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Timothy Schmid sold 403 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $165.22 on Thursday. The firm has a market cap of $397.79 billion, a P/E ratio of 24.85, a price-to-earnings-growth ratio of 2.56 and a beta of 0.52. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The business’s 50 day moving average is $152.11 and its 200-day moving average is $156.19.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the company earned $2.29 earnings per share. Equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were paid a dividend of $1.24 per share. The ex-dividend date was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.00%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 74.59%.

Analyst Upgrades and Downgrades

Several research analysts recently commented on JNJ shares. Leerink Partners reduced their price target on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Bank of America increased their price target on Johnson & Johnson from $159.00 to $171.00 and gave the company a “neutral” rating in a research report on Wednesday. Royal Bank of Canada reissued an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a research report on Wednesday, February 19th. Barclays increased their price target on Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research report on Tuesday, January 28th. Finally, Wolfe Research started coverage on Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 price target for the company. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $171.33.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.